🇺🇸 Inflammatory biomarkers dosage "Normothermia Arm" in United States

17,813 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 17,813

Most-reported reactions

1. Drug Ineffective — 2,076 reports (11.65%)
2. Off Label Use — 2,076 reports (11.65%)
3. Complication Associated With Device — 1,986 reports (11.15%)
4. No Adverse Event — 1,865 reports (10.47%)
5. Nausea — 1,818 reports (10.21%)
6. Acute Kidney Injury — 1,732 reports (9.72%)
7. Diarrhoea — 1,673 reports (9.39%)
8. Headache — 1,561 reports (8.76%)
9. Pain — 1,517 reports (8.52%)
10. Fatigue — 1,509 reports (8.47%)

Source database →

Frequently asked questions

Is Inflammatory biomarkers dosage "Normothermia Arm" approved in United States?

Inflammatory biomarkers dosage "Normothermia Arm" does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Inflammatory biomarkers dosage "Normothermia Arm" in United States?

Centre Hospitalier Departemental Vendee is the originator. The local marketing authorisation holder may differ — check the official source linked above.